|
|
|
| Experimental study on the optimized prescription of Danggui Shaoyao San against chronic pelvic inflammation |
| LIU Min WANG Xiaoyan JIA Ruilin REN Cunxia |
| College of Traditional Chinese Medicine, Inner Mongolia Medical University, Inner Mongolia Autonomous Region, Hohhot 010059, China |
|
|
|
Abstract Objective To observe the effects of the optimized composition of Danggui Shaoyao San combined with the Mongolian medicine Chipaozi on serum inflammatory factors and histopathology in chronic pelvic inflammatory disease (CPID) model rats. Methods Seventy female SD rats were randomly divided into seven groups, including normal group, model group, high, medium, and low-dose Xinfang group, Jingangteng group, and Mongolian medicine Chipaozi group with 10 cases in each group. The CPID model was reproduced by the method of bacterial planting and mechanical damage, and medication was administered four weeks later. The high, medium, and low-dose groups of the new prescription were given by intragastric administration at 19.74, 9.87 g/kg, and 4.93 g/kg, respectively. The Jingangteng group and the Mongolian medicine Chipaozi group were given by oral administration at 0.63 g/kg and 1.04 g/kg. The material was taken two weeks after the administration. Enzyme-linked immunosorbent assay (ELISA) was used to determine serum tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and IL-10 levels in rats in each group. The changes of rat uterine tissue under a microscope was observed and the pathology was scored. Results Compared with the normal group, the uterine pathology score of the model group was significantly increased, and the difference was highly statistically significant (P ＜ 0.01). The pathological score of Jingangteng group, high and medium Xinfang group were lower than that of model group, and the differences were statistically significant (P ＜ 0.05). Compared with the model group, the levels of IL-10 in the high and medium-dose Xinfang groups were increased, while the levels of IL-1β and TNF-α in the high, medium and low-dose Xingfang groups were decreased, and the differences were statistically significant (P ＜ 0.05). Compared with Jingangteng group, the content of TNF-α in the high and medium-dose Xinfang groups were decreased, and the differences were statistically significant (P ＜ 0.05). Compared with the Mongolian medicine Chipaonzi group, IL-10 in the high and medium-dose Xinfang groups were increased and IL-1β were decreased, and the differences were statistically significant (P ＜ 0.05). Conclusion The optimized prescription of Danggui Shaoyao San can counteract the abnormal expression of inflammatory cytokines in CPID model rats and improve the local pathological environment of model rats. The new prescription can promote the recovery of immune function by regulating the levels of TNF-α, IL-1β and IL-10 inflammatory factors, thereby exerting an active therapeutic effect on CPID model rats.
|
|
|
|
|
|
[1] 吴文湘，廖秦平.盆腔炎性疾病的流行病学[J].实用妇产科杂志，2013，29（10）：721-723.
[2] 覃师.浅析导致女性发生慢性宫颈炎及盆腔炎的相关因素[J].当代医药论丛，2020，18（7）：44-45.
[3] 韩美茹，张菁.经方当归芍药散治疗妇科疾病研究进展[J].亚太传统医药，2019，15（4）：199-201.
[4] 保艳.当归芍药散在妇科疾病中的应用[J].光明中医，2020，35（6）：910-912.
[5] 蒋姗珊，庞俏燕，王亚静，等.当归芍药散在妇科疾病中的运用[J].中医药导报，2020，26（8）：79-81，86.
[6] 高升，高飞，闫亚楠，等.当归芍药散对慢性盆腔炎大鼠外周血Th、Tc细胞和NO、IL-4、IL-10的影响[J].中药新药与临床药理，2016，27（4）：528-533.
[7] 张志鹏，高升，任存霞.当归芍药散对慢性盆腔炎模型大鼠分子免疫调控的影响[J].中华中医药学刊，2015，33（11）：2684-2686.
[8] 闫亚楠，刘敏，高升，等.采用正交设计析因分析法对当归芍药散治疗慢性盆腔炎模型大鼠的组方优化研究[J].中药药理与临床，2018，34（5）：11-15.
[9] 吴香杰，阎文玫.蒙药赤瓟子及其混淆品王瓜的鉴别研究[J].中草药，1995，25（3）：153-156，169.
[10] 金家红，颜为红，石孟琼，等.南赤瓟对宫颈癌HeLa细胞的作用[J].中药药理与临床，2013，29（3）：127-131.
[11] 辛宇，辛国.赤瓟果实提取物对多巴胺致胃轻瘫小鼠MTL、5-HT的影响[J].吉林中医药，2018，38（12）：1438-1440.
[12] 王隶书，岳乐乐，程东岩，等.中药赤雹的研究概述[J].中国药师，2016，19（3）：574-578.
[13] 张宏，王旭昀，刘美奇，等.中药含药血清实验动物灌胃给药剂量探讨[J].吉林中医药，2015，35（6）：623-625.
[14] 张海琴.慢性盆腔炎的证候规律调查及活血化瘀法调节T细胞亚群和红细胞免疫的实验研究[D].济南：山东中医药大学，2006.
[15] 关开，王晓男.当归芍药散治疗慢性盆腔炎的临床疗效观察[J].中医药信息，2017，34（2）：93-95.
[16] 孙书青，马秀君，陈凤娟.当归芍药散穴位敷贴对湿热瘀结型盆腔炎性疾病后遗症患者血液流变学和炎性因子的影响[J].临床合理用药杂志，2017，10（12）：91-92.
[17] 蒋洁茹，李雪梅.当归芍药散加减合熏洗剂治疗慢性盆腔炎疗效分析[J].深圳中西医结合杂志，2017，27（10）：53-54.
[18] 唐玉梅.蒙药治疗慢性盆腔炎的临床体会[J].世界最新医学信息文摘，2015，15（62）：157.
[19] 乌日娜.蒙药治疗慢性盆腔炎疗效观察[J].中国民族医药杂志，2017，23（3）：10-11.
[20] 乌恩岳苏.蒙医药治疗慢性盆腔炎的临床疗效研究[J].中国民族医药杂志，2018，24（7）：3-4.
[21] 任存霞.当归芍药散协同蒙药治疗慢性盆腔炎临证心得[J].中国民族民间医药，2018，37（10）：42-44.
[22] 齐武强，杨晓婷.抗生素联合金刚藤治疗盆腔炎性疾病临床观察[J].中国现代医生，2014，52（23）：37-39.
[23] 陈锦萍.康妇炎胶囊联合抗生素治疗盆腔炎性疾病后慢性盆腔痛患者的临床效果观察[J].临床合理用药杂志，2019，12（18）：17-18.
[24] 熊冰，王志萍，张波，等.慢性盆腔炎免疫抗炎机制的实验研究进展[J].广西中医药，2016，39（1）：8-11.
[25] 王晓静，李秀玉，腰向颖.三仁汤加减及药袋热敷治疗慢性盆腔炎伴积液的疗效及对粘连相关免疫分子的影响[J].四川中医，2016，34（7）：122-124. |
|
|
|
